Tampon GML Localization for TSST-1 Inhibition

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing tampon technologies face challenges in reducing Toxic Shock Syndrome toxin-1 (TSST-1) production by Staphylococcus aureus without causing excessive foaming and extractable issues, particularly when using glycerol monolaurate (GML) at concentrations that are not uniformly effective or sustainable.

Innovation Solution

Applying GML to only a portion of the fibers (e.g., 10%) or locating it on the tampon's cover, while blending GML-treated fibers with untreated fibers to achieve low add-on levels, thereby maintaining acceptable extractable and foaming properties while inhibiting TSST-1 production effectively.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If GML is added to tampons to reduce TSST-1 production, then toxin production is reduced, but foaming and extractable levels increase

Engineering Contradiction:
ImproveTSST-1 productionVSAvoidfoaming and extractable levels
Core Design Contradiction:
Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent applies GML non-uniformly to the tampon structure, specifically concentrating it on the cover (apertured film) rather than distributing it throughout all fibers. This localized application provides toxin-inhibiting contact surfaces where bacteria are most likely to encounter the product, while minimizing overall GML content to reduce foaming and extractable issues

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent segments the tampon into different functional zones: the cover contains GML for toxin inhibition, while the bulk absorbent fibers remain GML-free or have minimal GML. This segmentation allows the toxin-inhibiting function to be separated from the absorbent function, enabling effective toxin reduction without excessive GML addition throughout the entire product

Inventive Principle:
Principle #1Segmentation

2Reliability

If GML concentration is increased to ensure efficacy, then TSST-1 reduction is improved, but product purity and safety standards are compromised

Engineering Contradiction:
ImproveTSST-1 reduction efficacyVSAvoidpurity and safety standards compliance
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The patent optimizes GML concentration parameters by setting specific thresholds: up to 5 wt-% on the cover and less than 0.05 wt-% on fibers. These parameter adjustments ensure sufficient toxin-inhibiting contact on surfaces while maintaining overall product purity and compliance with safety standards through controlled low-level distribution in the fiber matrix

Inventive Principle:
Principle #35Parameter changes

3Object-affected harmful factors

If GML is applied uniformly to all fibers, then toxin inhibition is maximized, but foaming and extractable levels become excessive

Engineering Contradiction:
Improvetoxin inhibitionVSAvoidfoaming and extractable levels
Core Design Contradiction:
Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent creates non-uniform GML distribution by concentrating the additive on the cover where it provides maximum protective benefit during insertion and wear, while minimizing or eliminating GML from the bulk fiber absorbent material. This localized quality approach ensures toxin inhibition at critical interfaces without the penalties of uniform distribution

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly reduces TSST-1 production without adversely affecting S. aureus viability, while meeting purity and safety standards by controlling GML concentrations below 0.05 wt-% on fibers and up to 5 wt-% on covers, ensuring low levels of ether and water soluble substances and passing foaming tests.

Implementation Method 1

The published prior art reports the potential use of a surfactant, GML, as a fiber finish for tampons... GML can be retained on the fiber as compared with other known fiber finishes which are water soluble

Methodology Applied
Scientific EffectSurfactant activity: Surfactant

Implementation Method 2

GML solubility in water is much less than 10% and thus remains coated on the tampon materials to provide a continued benefit

Methodology Applied
Scientific EffectAdsorption: Adsorption

Data Source

PatentEP2700388B1Location of fatty acid esters on tampons and toxin inhibiting efficacy
Publication Date: 2016.04.06 JOHNSON & JOHNSON CONSUMER INC

AI summary

The application of active ingredients, exemplified by GML, to absorbent fibers, such as rayon fibers, used in tampon manufacture at very low levels has been found to maintain efficacy in the inhibition of the production of toxic shock syndrome toxin one (TSST-1) produced by S. aureus without overtly killing the microorganism to achieve the desired reduction while avoiding undesired test results that suggest the presence of "impurities" in some jurisdictions.